Our group identified that tumors with amplification of NECTIN4 had a 96 percent response to enfortumab vedotin, compared to only 32 percent in non-amplified. This could serve as a biomarker to select patients for enfortumab vedotin plus pembrolizumab, or even enfortumab vedotin alone, when there are other drugs in this space.
Last year, the FDA granted accelerated approval of a combination therapy, enfortumab vedotin antibody therapy plus pembrolizumab chemotherapy, for locally advanced or metastatic bladder cancer.
[
add
]
[
|
|
...
]